{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.1","upperLimit":"71.9","value":"6.29"},{"groupId":"OG001","lowerLimit":"4.7","upperLimit":"461.6","value":"12.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"TTR is defined as the time from date of randomization to date of first documented response (CR or PR) measured by investigator assessment per RECIST 1.1.\n\nCR: Disappearance of all lesions with lymph nodes measuring \\< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.\n\nPatients who had not achieved a confirmed CR or PR were censored at the last adequate tumor assessment date when they had not had a PFS event or at maximum follow-up when they had had a PFS event","dispersionType":"Full Range","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization. Patients with confirmed CR or PR by investigator assessment.","reportingStatus":"POSTED","timeFrame":"From randomization to date of first documented response, up to approximately 120 months","title":"Time to Response (TTR) by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Weeks"}